Lymphoma (Hodgkin, non-Hodgkin) – Symptoms, Treatment, and Immunotherapy Options in Malaysia

Lymphoma, including both Hodgkin and non-Hodgkin types, is a form of blood cancer that originates in the lymphatic system — a critical part of the body’s immune defense. Lymphoma is one of the most treatable cancers when diagnosed early, and recent advancements in cell therapy and immunotherapy are improving outcomes for patients worldwide.

At RCERT (Regional Cell Research & Therapy Centre), we offer advanced, personalized approaches to lymphoma treatment, including Natural Killer (NK) cells, CAR-T cells, DC-CIK cell combinations, and immune-based supportive therapies — designed to restore health through cellular precision and innovation.

🧬 What Is Lymphoma?

Lymphoma is a cancer of the lymphocytes, which are a type of white blood cell. These cells help the body fight infections. When lymphocytes grow and multiply uncontrollably, they can form tumors in lymph nodes or spread to other parts of the body like the spleen, liver, bone marrow, or even the brain.

There are two main types:

🔹 Hodgkin Lymphoma (HL)

Characterized by the presence of abnormal cells called Reed-Sternberg cells. Hodgkin lymphoma is less common and tends to occur in younger adults (ages 15–35) or older adults (over 55).

🔹 Non-Hodgkin Lymphoma (NHL)

A diverse group of blood cancers affecting B-cells or T-cells. Non-Hodgkin lymphoma is more common and occurs in a wide age range. NHL subtypes vary in aggressiveness — from slow-growing (indolent) to fast-growing (aggressive).

🩺 Common Symptoms of Lymphoma

Patients with Hodgkin or non-Hodgkin lymphoma may experience:

• Painless swelling of lymph nodes (neck, armpit, or groin)

• Persistent fatigue

• Fever and chills

• Night sweats

• Unexplained weight loss

• Itchy skin or rash

• Chest pain or cough (if lymph nodes swell near lungs)

• Abdominal bloating or fullness

These symptoms may mimic other conditions, so proper diagnostic testing is essential.

🧪 Diagnosis and Staging

To diagnose lymphoma, physicians typically perform:

• Blood tests (CBC, LDH)

• Lymph node biopsy (confirm cancer cell type)

• PET/CT scans (to assess spread)

• Bone marrow biopsy (to check marrow involvement)

• Molecular testing (to classify subtypes and genetic markers)

Lymphoma is staged from I (localized) to IV (advanced), which guides treatment plans.

💊 Standard Treatments for Lymphoma

For Hodgkin Lymphoma:

• ABVD chemotherapy regimen

• Radiation therapy (for localized disease)

• Stem cell transplant (in relapse)

• Immunotherapy (e.g., checkpoint inhibitors like nivolumab)

For Non-Hodgkin Lymphoma:

• CHOP chemotherapy

• Rituximab (monoclonal antibody)

• Radiation therapy

• Targeted therapy or CAR-T therapy (for certain types)

• Autologous stem cell transplant

Treatment choice depends on the subtype, stage, and patient’s health.

🧬 Cell Therapy Options for Lymphoma at RCERT

RCERT provides advanced immune cell therapy and personalized medicine approaches that are increasingly effective for both Hodgkin and non-Hodgkin lymphoma, especially for relapsed or refractory cases.

1️⃣ CAR-T Cell Therapy

Genetically engineered T cells designed to target CD19-positive B-cell lymphomas. CAR-T cells have shown remarkable results in aggressive NHL and have been approved globally for this use.

2️⃣ NK Cell Therapy (Natural Killer Cells)

RCERT’s autologous or donor-derived NK cells help recognize and kill lymphoma cells without prior sensitization. These cells are especially useful for immune boosting after chemotherapy.

3️⃣ DC-CIK Therapy

A combination of dendritic cells (DC) and cytokine-induced killer (CIK) cells, designed to stimulate an adaptive immune attack against lymphoma cells.

4️⃣ DC-CTL Therapy

T cells trained by dendritic cells to target lymphoma-specific antigens, offering high precision and long-term memory against recurrence.

🔬 Benefits of Cell-Based Immunotherapy

• Targets cancer cells with minimal harm to healthy cells

• Works even in drug-resistant lymphoma cases

• Enhances immune system function

• Supports recovery post-chemotherapy

• Personalized to each patient’s immune profile

At RCERT, our cell therapies are cultivated in GMP-certified laboratories, and administered under clinical-grade protocols, often in combination with conventional therapies for improved outcomes.

📊 Research and Innovation at RCERT

RCERT is actively engaged in clinical studies and cell therapy innovation for lymphoma patients in collaboration with:

• UNIMAS (Universiti Malaysia Sarawak)

• Zhongrong Cell Technology Center, China

Our research is focused on developing combinational therapies using:

• NK + DC-CIK

• CAR-T + DC-CTL

• Exosomes for immune modulation

• Genetic markers for better lymphoma stratification

These approaches help us tailor treatment to each patient’s cancer subtype and immune readiness.

👤 Who Is a Candidate for RCERT Cell Therapy?

Cell-based immunotherapy may be suitable for:

• Patients with relapsed or refractory lymphoma

• Individuals who have not responded to chemotherapy

• Patients seeking non-toxic or personalized treatment

• Those preparing for or recovering from stem cell transplant

• Participants in clinical trial protocols

A detailed immune screening and medical evaluation is conducted before initiating any therapy.

⚖️ Safety and Side Effects

RCERT’s therapies are conducted with strict adherence to medical safety protocols. While most patients tolerate cell therapy well, possible side effects may include:

• Mild fever or fatigue

• Injection site inflammation

• Temporary drop in white blood cell count (with pre-conditioning)

Unlike chemotherapy, cell therapy does not cause hair loss, nausea, or immune suppression.

📍 Lymphoma in Malaysia – A Growing Concern

According to Malaysia’s National Cancer Registry, non-Hodgkin lymphoma is among the top 10 most common cancers in the country. Hodgkin lymphoma, though less prevalent, is increasingly detected in younger adults.

RCERT is working to address this burden by:

• Offering localized access to advanced immunotherapy

• Training healthcare providers in immune profiling

• Building partnerships to improve patient outreach and education

📝 Conclusion

Lymphoma (Hodgkin and non-Hodgkin) is a treatable cancer — especially when approached with early detection, appropriate clinical care, and access to advanced therapies. At RCERT, we are pushing the boundaries of cancer care through cell therapy, immunotherapy, and translational research.

Whether you’re newly diagnosed, in relapse, or exploring second-line treatments, our medical team is here to guide you with personalized, science-backed options.

📞 Ready to explore immunotherapy for lymphoma?
Contact RCERT today to schedule a consultation or refer a patient.